CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 148 enrolled
Drug / intervention
Calcium acetate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00785629
NCT00785629N/ACompleted
CompareCT.gov

A Double Blind Randomized Placebo Controlled Trial of Maintenance of Normal Serum Phosphorus in Chronic Kidney Disease (CKD)

Denver Nephrologists, P.C.·interventional·Posted Nov 5, 2008·Updated Oct 30, 2012

In Brief

A clinical study evaluating Calcium acetate, Lanthanum Carbonate, and 2 other interventions for Chronic Kidney Disease. Completed, enrolled 148 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
CollaboratorsShire, Fresenius Medical Care North America, Genzyme, a Sanofi Company, Novartis Pharmaceuticals, DaVita, Inc.

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 5, 2008
Enrollment StartFeb 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.7 years ago

Interventions

Calcium acetatedrug

Lanthanum Carbonatedrug

Sevelamer Carbonatedrug

Placebodrug